Core Viewpoint - On November 11, Hainan Pharmaceutical experienced a 5.08% increase in stock price, reaching 57.13 CNY per share, with a trading volume of 204 million CNY and a turnover rate of 4.48%, resulting in a total market capitalization of 6.856 billion CNY [1] Company Overview - Nanjing Hainan Pharmaceutical Co., Ltd. was established on January 15, 2003, and listed on January 12, 2017. The company specializes in the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The revenue composition of the company's main business includes: cardiovascular drugs 87.12%, antibiotics 5.69%, active pharmaceutical ingredients and intermediates 1.68%, digestive drugs 1.50%, antiviral drugs 1.47%, and other categories [1] Shareholder Information - Yongying Fund has a fund that ranks among the top ten circulating shareholders of Hainan Pharmaceutical. The Yongying New Materials Smart Selection Mixed Fund A (024737) entered the top ten shareholders in the third quarter, holding 482,400 shares, which accounts for 0.59% of the circulating shares. The estimated floating profit today is approximately 1.3314 million CNY [2] - The Yongying New Materials Smart Selection Mixed Fund A (024737) was established on July 28, 2025, with a latest scale of 71.9734 million CNY and a return of 19.26% since inception [2] Fund Manager Profile - The fund manager of Yongying New Materials Smart Selection Mixed Fund A (024737) is Ou Zichen. As of the report, Ou has been in the position for 3 years and 278 days, managing total assets of 2.624 billion CNY. The best fund return during his tenure is 88.41%, while the worst return is -11.01% [3]

Group 1 - The core viewpoint of the news is that Hainan Pharmaceutical has seen a stock price increase of 5.71%, reaching 59.10 CNY per share, with a total market capitalization of 7.092 billion CNY as of the report date [1] - The company, Nanjing Hainan Pharmaceutical Co., Ltd., was established on January 15, 2003, and went public on January 12, 2017. Its main business includes the research, production, and sales of chemical preparations, active pharmaceutical ingredients, and intermediates [1] - The revenue composition of the company's main business is as follows: cardiovascular drugs 87.12%, antibiotics 5.69%, active pharmaceutical ingredients and intermediates 1.68%, digestive drugs 1.50%, antiviral drugs 1.47%, others (supplements) 0.83%, immune regulators 0.80%, other categories 0.57%, and diuretics 0.34% [1] Group 2 - Among the top circulating shareholders of Hainan Pharmaceutical, Yongying Fund has a fund that entered the top ten shareholders in the third quarter, holding 482,400 shares, which accounts for 0.59% of the circulating shares [2] - The fund, Yongying New Materials Smart Selection Mixed Initiation A (024737), was established on July 28, 2025, with a latest scale of 71.9734 million CNY and has achieved a return of 14.22% since its inception [2] Group 3 - The fund manager of Yongying New Materials Smart Selection Mixed Initiation A is Ou Zichen, who has been in the position for 3 years and 272 days. The total asset scale of the fund is 2.624 billion CNY, with the best fund return during the tenure being 85.31% and the worst being -11.01% [3]

Group 1 - Zhongyi Technology (301150.SZ) reported its Q3 2025 results on October 27, 2025, with a total of 10 institutional investors disclosing their holdings, amounting to 28.3292 million shares, which represents 12.15% of the total share capital [1] - The top ten institutional investors include Yunmeng Zhongyi Technology Investment Center (Limited Partnership), Jiangsu Yueda Automobile Group Co., Ltd., and others, with their combined holding percentage decreasing by 2.08 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, four new public funds were disclosed this period, including Invesco Great Wall New Energy Industry Equity Class A and others, while 38 public funds were not disclosed compared to the previous quarter [2] Group 3 - One new social security fund disclosed its holdings in Zhongyi Technology, specifically the National Social Security Fund 116 Portfolio [3]